Continuous versus on-demand pharmacotherapy of allergic rhinitis: Evidence and practice  by Laekeman, Gert et al.
Respiratory Medicine (2010) 104, 615e625ava i lab le at www.sc ienced i rec t . com
journa l homepage : www.e lsev ier . com/ loca te / rmedREVIEW
Continuous versus on-demand pharmacotherapy of
allergic rhinitis: Evidence and practiceGert Laekeman a,*, Steven Simoens a, Johan Buffels b, Michel Gillard c,
Thibert Robillard d, Margherita Strolin Benedetti e, Jean-Baptiste Watelet f,
Georges Liekendael g, Liesbet Ghys g, Martin Church h,ia Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven, Onderwijs en
Navorsing 2, Herestraat 49, P.O. Box 521, 3000 Leuven, Belgium
b Department of General Practice, Katholieke Universiteit Leuven, BE 3000 Leuven, Belgium
c Department of Pharmacology, UCB Pharma sa, BE 1420 Braine l’Alleud, Belgium
d Clinique St-Elisabeth, BE 5000 Namur, Belgium
e Department of Pharmacokinetics, UCB Pharma sa, 92000 Nanterre, France
f Division of Otho-, Rhino- & Laryngology, University Hospital Ghent, BE 9000 Ghent, Belgium
g UCB S.A. Belgium, BE 1070, Brussels, Belgium
h University of Southampton School of Medicine, Southampton SO16, United Kingdom
i Allergie-Centrum-Charite´/ECARF, Charite´-Universita¨tsmedizin Berlin, Germany
Received 17 April 2009; accepted 10 January 2010
Available online 16 February 2010KEYWORDS
Allergic rhinitis;
Continuous treatment;
On-demand treatment;
Pharmacotherapy* Corresponding author. Tel.: þ32 (0
E-mail address: gert.laekeman@ph
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2010.01.006Summary
This review aims to compare continuous with on-demand pharmacotherapy of allergic rhinitis
by focusing on pharmacodynamic, pharmacokinetic, safety, effectiveness, cost and cost-effec-
tiveness considerations. A working party of experts reviewed and discussed the literature and
guidelines, and conducted a qualitative analysis of the Summary of Product Characteristics of
specific medicines. With respect to medicines, the working party limited itself to antihista-
mines, nasal corticosteroids and leukotriene antagonists. Based on a review of the evidence
from a multidisciplinary perspective, this article makes pharmacotherapeutic recommenda-
tions that are easy, functional and applicable to daily practice in primary care.
The pharmacotherapeutic evidence for continuous versus on-demand treatment of allergic
rhinitis was limited. Clearly, for corticosteroids, their mechanism of action in allergic rhinitis
of reducing allergic inflammation requires continuous therapy at least for the duration of
symptoms. For H1-antihistamines, some trials suggest that continuous treatment is preferable)16 323415; fax: þ32 (0)16 323468.
arm.kuleuven.be (G. Laekeman).
0 Elsevier Ltd. All rights reserved.
616 G. Laekeman et al.but more studies are needed to confirm this conclusion. For both H1-antihistamines and nasal
corticosteroids safety data indicate that continuous treatment may be given without fears of
adverse consequences, although a distinction can be made between the first and the second
generation antihistamines. With regard to the cost and cost-effectiveness implications of
continuous therapy versus on-demand therapy, more studies are necessary before definitive
conclusions may be made.
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An estimated 20e30% of the adult population in the
western world is affected by allergic rhinitis. According to
some sources 1 out of 5 children is sensitive to inhalant
common allergens. Others estimate to over 40% the number
of children suffering from this condition.1e3
Allergic rhinitis is not life-threatening and considered by
many to be a trivial disease with mild symptoms. However,
sufferers tell a different story. Assessment of the disease
through both general health questionnaires and disease
specific questionnaires shows a dramatic impairment of the
quality of life and usual daily activities with the patients with
more severe disease experiencing the highest level of
impairment.4 Although the presence of the symptoms is
perceived as a disturbing element in itself, in a recent patient
survey, 85% of the patients felt that their daily activities,
particularly those relating to their professional, personal and
social life, their outdoor activities and their ability to func-
tion properly at work or at school and their sleep were
impaired either moderately or severely.5 Furthermore,
a large proportion of patients report that their disease causes
sleep disturbances, such as trouble in going to sleep or
awakening during the night and more than 50% report that
they felt tired uponwaking.5e7 In a survey performed in South
Africa in 1181 patients with allergic rhinitis, symptoms of
allergic rhinitis affected the quality of sleep in 76.6% of
sufferers and for more than a third this was every night.8
Almost 40% of children suffering from allergic rhinitis
reported that they have to miss school due their disease.5
In addition, allergic rhinitis can impair cognitive function
and compromise learning, placing afflicted children ata disadvantage. In a survey of 83 adolescents with seasonal
allergic rhinitis, 78% reported that they had difficulty doing
schoolwork, 75% could not concentrate on solving problems
and 70% were less able to get school activities accom-
plished.9 In addition, both the acquisition and application
of knowledge are slowed and short-term memory is reduced
in allergic children compared with healthy children.10
In adults, allergic rhinitis can also be a cause of both
work absenteeism and of reduced work performance with
an European survey finding that a quarter of patients had to
take time off work due to their disease.5 These figures were
confirmed in another population-survey11 which assessed
the relative impacts on work loss and decreased produc-
tivity of allergic rhinitis and asthma in 400 adults in
Northern California. The results showed that work loss,
assessed as any partial or complete lost work days during
the previous 4 weeks due to the condition, was similar in
the two conditions, 23% for allergic rhinitis and 24% for
asthma. However, of those persons who stayed at work and
tried to ‘‘work through’’ their symptoms, 36% of patients
with allergic rhinitis were less effective at their jobs
compared with 19% for asthma.11 These data suggest that
allergic rhinitis, which is more common than asthma, may
actually have a bigger impact among those who stay at work
‘‘working through’’ their symptoms.
As allergic rhinitis is one of the most frequent diseases
encountered in clinical practice, the cost implications to
society are enormous.12 It was calculated that in the United
States in 1994, there were 811,000 missed workdays,
4,230,000 reduced productivity days, and 824,000 school
absences caused by allergic rhinitis.13 These work and
school lost days account for a significant economic loss (for
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mated to $13,000,000). For 1996, it was calculated that the
direct financial cost of rhinitis in the United States excee-
ded $3 billion and there were additional costs of $4 billion
for its effect on concomitant conditions such as asthma and
otitis.14 In Germany, the average annual cost of seasonal
allergic rhinitis has been estimated to be V1089 per child/
adolescent and V1543 per adult15 while a study using 2002
French costing data calculated an annual cost of V4260 per
patient for allergic rhinitis of which only 2% could be
attributed to direct medical costs, the remainder consti-
tuted by workdays lost due absence from work or poor
productivity and the inability to perform usual daily
activities.16
These facts justify the search for optimizing the phar-
macotherapy of allergic rhinitis. The main objective of this
review is to find an answer to the research question: what is
the pharmacotherapeutic evidence supporting continuous
treatment of allergic rhinitis in comparison with an on-
demand regimen? The purpose is to make recommendations
applicable to daily practice. The recommendations should
be easy and functional to primary care. They must be based
upon a multidisciplinary approach.Methodological considerations
In order to make a multidisciplinary approach, a working
party with experts in the field of pharmacology, pharma-
cokinetics, pharmacotherapy, pharmaco-epidemiology and
pharmacoeconomics was formed.
The activities of the working party had to yield a draft
paper containing: (a) a survey of evidence and expert
opinions; (b) an identification of the knowledge gaps; (c)
a summary of the findings and recommendations; (d)
a proposal for future research initiatives.
To reach the objectives five physical meetings of the
working party took place over a period of 18 months to
discuss the evidence on these questions.
During the first meeting a concept paper was discussed.
The outcomes of this meeting were defined as actions: (a)
each member should have taken a task according to the
concept agreed upon; (b) a time schedule for delivering
draft working papers. During the second meeting the first
draft papers were discussed and a time schedule was
accepted to deliver a second draft. During the third
meeting a schedule of a manuscript for publication was
agreed upon, starting from the draft papers. Because the
working papers were mostly quite extensive, limits had to
be set of what could be incorporated. The fourth meeting
was organised in order to comment the first draft of the
manuscript. The fifth meeting was the decisive one with
regard to the content of the manuscript. From that
time on the e mostly formal e finalising was left to one
principal author.
The members of the working party reviewed the litera-
ture and guidelines, and conducted a qualitative analysis of
the Summary of Product Characteristics (SmPC) of specific
medicines. The working party limited itself to antihista-
mines, nasal corticosteroids and leukotriene antagonists as
the therapeutic agents and considered the following
questions: What is the clinical approach used at present with
regard to continuous or ‘on-demand’ therapy?
 Do pharmacokinetic and pharmacodynamic consider-
ations indicate a preference for continuous or ‘on-
demand’ therapy?
 To what extent do safety considerations influence the
choicebetweencontinuous versus ‘on-demand’ therapy?
 What are the cost and cost-effectiveness implications
of continuous therapy versus ‘on-demand’ therapy?
Cochrane reviews, Web of Science, PubMed and Interna-
tional Pharmaceutical Abstracts were used as scientific
databases. The following search terms were all or not
combined: allergic, allergy, antihistamine, antileukotrienes,
atopic, benefit, congestion, corticosteroids, cost, contin-
uous, decision, duration, guideline, kinetic, leukotriene,
nasal, on-demand, outcome, pharmacoeconomic, pharma-
cology, risk, side effects, sneezing, steroids, symptomatic,
symptoms, therapeutic, therapy.
When selecting the studies, special attention was paid to
the continuous versus on-demand concept and the duration
of therapy. Searches were made in parallel with different
search terms as entry. The outcomes of these searches
were discussed during the meetings of the working party
and selection of references was made by consensus.
This study was carried out as part of the Supportive
Initiatives for the Global Management of Allergy (SIGMA) of
the UCB Institute of Allergy.
What is the clinical approach used at present
with regard to continuous or ‘on-demand’
therapy?
The ARIA (Allergic Rhinitis and its Impact on Asthma) guide-
lines in 200317 and updated most recently in 200818 were the
first to recommend an international approach to the treat-
ment of allergic rhinitis. According to these guidelines first
line treatment of allergic rhinitis consists of three steps:
1. oral or intranasal H1-antihistamines with limited use of
decongestants for mild intermittent rhinitis
2. oral or intranasal H1-antihistamines or intranasal
corticosteroids with limited use of decongestants and
chromones for moderate-to-severe intermittent and
mild rhinitis
3. intranasal corticosteroids with step-down and step-up
options, in conjunction with H1-antihistamines, nasal
decongestants, ipratropium and oral corticosteroids for
moderate-to-severe persistent rhinitis
The three-step approach seems easy to put into prac-
tice. But as clear-cut it may be, some considerations have
to be made with regard to symptoms and co-pathology. In
the ARIA guidelines special attention is given to co-
morbidities, as allergic inflammation does not limit to the
nasal airway. In case allergic rhinitis is accompanied by
asthma, the inhaled therapy becomes continuous as from
GINA step 2. In case the allergic rhinitis is not compli-
cated by any co-morbidity, the level of severity should be
taken into account when making the therapeutic
approach. Starting from the symptoms a pharmacological
618 G. Laekeman et al.management can be proposed, according to the ARIA
guidelines.
 Sneezing: intranasal corticosteroids, oral or intranasal
antihistamines.
 Rhinorrhea: intranasal corticosteroids, oral or intra-
nasal antihistamines, nasal anticholinergics.
 Nasal obstruction: oral decongestants, intranasal
corticosteroids, antileukotrienes.
 Nasal itching: oral or nasal antihistamines, nasal
corticosteroids.
 Eye symptoms: intraocular antihistamines, oral anti-
histamines, intranasal corticosteroids, intraocular
chromones, antileukotrienes.
Of the above-mentioned medicines, oral decongestants
should be used for a few days, especially in patients with
cardiovascular co-morbidity, benign prostate hyperplasia,
sleep disturbances and glaucoma.17
For mild intermittent rhinitis, the treatment should be
when necessary and of short duration. For moderate-to-
severe intermittent, the treatment should be continued to
prevent the development of persistent rhinitis. For persis-
tent rhinitis, continuous treatment is considered as more
efficient than ‘on-demand’ therapy. Antihistamines and
intranasal corticosteroids are perceived as being more
effective if the therapy is continuous.19
The analysis of the SmPC of 24 medicines revealed that,
apart from the leukotriene antagonists and some oral
glucocorticoids, all other medicines contained the labelling
‘allergic rhinitis’ or ‘allergic conditions of the respiratory
tract’. Symptomatic as well as prophylactic and chronic
treatment is mentioned in the indications.
Divergent information is given on the duration of treat-
ment for different drugs:
 Oral decongestants: the duration of treatment should
be as short as possible
 H1-antihistamines: mostly no instructions with regard to
duration of therapy are given. Cetirizine and levocetir-
izine are most explicit with specific durations according
to the complaints. For both products time limits are
specified (e.g. 3e6weeks for levocetirizine in case of hay
fever). Most probably limited experience in clinical trials
causes this warning (SmPC dated January 2004), as for
cetirizine clinical experience covers at least one year
 Local corticosteroids: it is recommended to use the
spray ‘regularly’, preventively or continuously
 Oral corticosteroids: use of betamethasone is
restricted to 10e14 days
 Sodium cromoglycate: preventive treatment does not
allow an interruption of treatment
What do we learn from clinical studies focusing
on continuous or ‘on-demand’ therapy?
H1-antihistamines
Only two studies specifically designed to compare contin-
uous versus on-demand therapy, both from the same
research group, were retrieved. Some comparative datawere also obtained from a third study used to assess the use
of rescue medication in children. Quantitative data from
these studies are given in Table 1.
In the first study,20 cetirizine was administered either
continuously or on-demand to twenty adults with seasonal
allergic rhinitis over a 4-week period of natural allergen
exposure during the pollen season. The results showed that
patients treated with continuous therapy achieved signifi-
cant symptomatic relief and inflammatory control
(decreases in numbers of infiltrating neutrophils and
eosinophils) in comparison to patients treated on-demand.
Interestingly, the authors comment that whereas contin-
uous treatment reduces clinical and inflammatory variables
more than on-demand therapy, the on-demand therapy can
achieve acceptable clinical control but does not reduce
allergic inflammation. Furthermore, the cost of therapy is
lower for on-demand treatment.
The second study,21 compared two parallel groups of 31
adults with persistent allergic rhinitis, one group taking
levocetirizine daily and the other taking it on-demand for
six months. Both treatment regimens considerably
decreased the total and individual symptom scores from
baseline and achieved similar levels up to week 14.
Continuous treatment was generally better than on-
demand from week 15 onwards, reaching statistical signif-
icance from weeks 17e21 (from week 19 to 21 for nasal
pruritus). Both regimens substantially improved quality of
life and sleep quality. The authors concluded that contin-
uous therapy showed a trend to be more effective in
controlling the symptoms of rhinitis, improving quality of
life and decreasing nasal inflammation compared with on-
demand therapy.
The third study22 evaluated whether cetirizine admin-
istered regularly for 24 weeks reduced allergic symptoms
and the use of rescue medications, such as antibiotics,
paracetamol, b2-agonists, inhaled and systemic cortico-
steroids, in children with persistent allergic rhinitis and
asthma due to house dust mite allergy. The results
showed that symptom scores and consumption of rescue
medication were significantly lower (P< 0.05) in the
cetirizine-treated group versus the placebo group.
Furthermore, the cost of treatment was lower with
continuous therapy because more co-medication was
taken in the placebo group due to poorer symptom
control.
There is a suggestion from a small-scale study with
children that long-term cetirizine treatment may reduce
new sensitisations in monosensitised children. The study
included two groups of 10 children with mite allergy,
receiving either cetirizine or placebo daily. Cetirizine
could be used as rescue medication. After six months
continuously treated children remained on cetirizine
during the following three years. The other children were
treated on-demand during the same period. After 3 years
only 2 continuously treated children showed poly-
sensitization versus 5 symptomatically treated children.
After 6 years the results were respectively 7 versus 9.
(PZ 0.002).23
The results of these pilot studies support the continuous
use of antihistamines as being more effective than on-
demand therapy. The observation that inflammatory vari-
ables, such as nasal congestion, are suppressed better by
Table 1 Comparison of continuous versus on-demand therapy with cetirizine and levocetirizine.
Reference Patients Intervention Outcome
Ciprandi
et al., 1997
DBeRePl
NZ 20 (19e48 years)
(11 men/9 women)
Rhinoconjunctivitis
due to pollen
Natural pollen exposure
Cetirizine 10 mg/day or Pl
for 4 weeks
C or OD
Rescue medicationZ
cetirizine 10 mg/day
Nasal symptoms: C<OD:
from 3rd week*
Rescue medication: C<OD:
from 1st week**
Neutrophils/eosinophils: C<OD:
at 4 weeks **
Cost of therapy: OD< C
Ciprandi
et al., 2001
DBeRePl
NZ 20 (3e10 years)
(15 boys/5 girls)
Rhinoconjunctivitis
(house dust mite)
and/or mild
intermittent asthma
Cetirizine drops 5 mg/day
for 24 weeks
Rescue medicationZ
Cetirizine 5 mg/day
Salbutamol 1 or 2 puffs of 100 mg
Fluticasone 2 puffs of 125e250 mg
Oral deflazacort 1 mg/kg
AB or acetaminophen if needed
Weekly rhinitis symptoms:
C<OD: 11 weeks on 24*
Weekly asthma symptoms:
C<OD: 6 weeks on 24*
Additional drug intake:
C<OD 16 weeks on 24
Additional cetirizine intake:
C<OD***
Cost of therapy: C (191.83US $)
<OD (278.54US $)
Canonica et al., 2008
ReOeP
NZ 62 (31 in each group)
Persistent allergic rhinitis
Levocetirizine 5 mg/day
for 6 months
C or OD
Drop outZ 22/62
CZOD up to week 14
C>OD from week 17 on*
The abbreviations used are: DBZ double blind, OZ open label, RZ randomized, PZ parallel, PlZ placebo, CZ continuous,
ODZ on-demand, ABZ antibiotics. Significance levels are indicated by; *P< 0.05, **P< 0.01, ***P< 0.001.
Therapy of allergic rhinitis: continuous or on-demand? 619continuous therapy supports the hypothesis that reduction
of allergic inflammation requires long-term therapy with
antihistamines.14,24 However, there is a need for more
clinical evidence, particularly with other antihistamines. In
addition, pharmacological and pharmacokinetic parame-
ters could help to look for a certain level of evidence. The
studies mentioned above cannot be considered as pivotal:
the number of patients per treatment group was low,
especially when placebo was included in the study design. A
type 1 statistical error (Zoutcome false positive) cannot be
excluded.
Nasal corticosteroids
Local administration of corticosteroids to the nose has
three primary effects:
 A vasoconstrictor effect which develops slowly over
a period of up to 72 h25
 A reduction of allergic inflammation following down-
regulation of pro-inflammatory cytokines involved in
the recruitment and activation of inflammatory cells,
including eosinophils, dendritic cells and T-lympho-
cytes.26,27 These effects become apparent only slowly,
taking days or even weeks to become maximal.
 A reduction of mast cell accumulation and maturation
resulting from the downregulation of the transcription
of stem cell factor, the primary growth factor for mast
cells.28 This is the slowest of the effects to become
apparent due to the long life span of mast cells in
allergic responses.29
The ‘lag’-time before significant therapeutic results are
obtained with intranasal corticosteroids differs from studyto study being dependent both on the glucocorticoid used
and the experimental conditions. The fastest response for
significant changes in the nasal index score and peak nasal
inspiratory flow has been obtained 4 h after the first
administration of nasal budesonide or mometasone.30 In
another study31 mometasone improved the composite nasal
and non-nasal symptom score after 5 h but required 7 h to
reduce nasal symptoms.
While the above studies show that statistically signifi-
cant improvement may occur quite rapidly, it takes much
longer for nasal corticosteroids to become truly effective.
For example, by 12 h after the first administration of
mometasone during the pollen season, only 28% of patients
experienced clinically significant relief 28% while by 72 h
64% of the patients experienced at least moderate relief.32
In another study, 4e8 days was needed for significant
clinical improvement with beclomethasone and mometa-
sone.33 Patients on mometasone and beclomethasone have
less non minimal symptom days as compared to placebo
after 2 days. The proportion of symptom free days was 83%
(mometasone), 77% (beclomethasone) and 64% (placebo).
The difference with placebo was significant for both active
treatments (P< 0.01).34
In most studies with nasal corticosteroids, patients have
at least one week of treatment before the first assessment
is made. Sometimes there is significant relief after one
week of the daytime, but not the night-time symptoms35
Even for provocation tests, at least two weeks pre-treat-
ment is often given.36 Also, whether the scoring is per-
formed by the physician or by the patient can make
a difference. In one study,37 subjective assessments made
by the physician showed a clinical difference after one
week whereas assessments by the patients themselves
required two weeks to achieve significant differences.
Figure 1 [1] Challenge of allergic rhinitis can be multifold. Causal relationship between pollen en seasonal allergy is fading as
pollen seem to penetrate into the bronchioles. [2] Allergic rhinitis has a considerable influence on professional performance
and cannot be foreseen in all circumstances. Direct as well as indirect costs play a role when considering the interference.
[3] Medicines can be prescribed according to guidelines. The prescription can have an intermittent or a continuous character.
[4] Treatment can be systemic (antihistamines, leukotriene antagonists) or local (corticosteroids, antihistamines). [5] There is
a lag-time between starting the pharmacotherapy and the onset of action. [6] Intermittent and continuous therapies are not
hampered by serious side effects.
620 G. Laekeman et al.As continuous therapy with corticosteroids may reduce
mast cell numbers,38 some authors strongly recommend
starting the treatment with nasal glucocorticoids before
the pollen season to achieve a prophylactic reduction of
mast cells in the nasal epithelium. To this end, the SmPC for
mometasone states: .The start of the pollen season may
vary, depending mainly on the geographic area and the
prevailing weather conditions, so ‘safe’ advice is to start
pre-treatment 2 to 4 weeks before start of the pollen
season and to continue treatment throughout the pollen
season.. The study that stimulated this recommendation39
was one which started administration of nasal mometasone
as prophylactic treatment 2e4 weeks before the pollen
season and continued for four months. An overwhelming
majority of patients (84%) were satisfied with this type of
treatment. There was, however, no control group, as this
was ‘a real life’ study.
Thus, with corticosteroids, which act primarily to reduce
allergic inflammation, continuous therapy is essential for
them to be clinically effective.To what extent do safety considerations
influence the choice between continuous
versus ‘on-demand’ therapy?
For drugs used for symptomatic relief of non-lethal condi-
tions, such as allergic diseases, safety is of paramount
importance. As no comparative data are available forcontinuous versus on-demand therapy with respect to
safety, this review will consider the long-term safety
aspects of antihistamines and intranasal corticosteroids in
relation to their use in both situations.
H1-antihistamines
It is now over 65 years since the introduction of phenox-
ybenzamine, the first H1-antihistamine introduced for clinical
use.40 It should be remembered that the first-generation
antihistamines came from the same chemical stem as anti-
cholinergic drugs, a stem from which tricyclic antidepres-
sants, antipsychotics and many other drugs were developed.
Indeed, the antihistamine, promethazine, was initially intro-
duced as an antipsychotic drug. As a consequence, first-
generation antihistamines are associated with a number of
adverse events, including central nervous system depression
and anticholinergic and cardiovascular effects. Nevertheless,
first-generation H1-antihistamines, including dexchlorphenir-
amine, diphenhydramine, hydroxyzine and promethazine are
still regularly used.
The introduction of terfenadine in 197841 saw the first of
the minimally sedating H1-antihistamines, a list which now
contains many drugs including azelastine, cetirizine,
desloratadine, ebastine, fexofenadine, levocetirizine and
loratadine. Second generation H1-antihistamines are rec-
ognised as being highly effective treatments for allergic
disease and are among the most frequently prescribed and
safest drugs in the world.42 There are many second
Therapy of allergic rhinitis: continuous or on-demand? 621generation H1-antihistamines available and at first exami-
nation these appear to be comparable in terms of safety
and efficacy. However, the newer antihistamines in fact
represent a heterogeneous group of compounds, having
markedly differing chemical structures, physico-chemical
properties, pharmacokinetic characteristics (e.g. half-lives
of elimination, protein binding, tissue distribution, abso-
lute bioavailability), being differently recognised by drug
metabolising enzymes and transporters, and producing
different adverse effects.
When comparing the duration of action with the plasma
elimination, there is not always a concordance. First-
generation antihistamines tend to have a longer plasma
halflife as compared to their duration of action. That is in
contrast with the second generation antihistamines where
duration of action mostly exceeds the plasma elimination
halflife. Translated into risk-benefit it means that circu-
lating concentrations of first-generation antihistamines can
still have secondary effects without resulting in therapeutic
benefits. Respecting therapeutic regimens with first-
generation antihistamines in order to obtain a 24 h
protection against allergic symptoms may provoke unnec-
essary side effects. Theoretically the second generation of
antihistamines may allow for a continuous therapy without
imposing a kinetic burden on the patient (see Table 2). As
all first-generation antihistamines are Over-The-Counter
(OTC) medicines, it should be carefully examined which
type of antihistamine should be delivered. When no addi-
tional anticholinergic activity is wanted, second generation
antihistamines are preferable.43 The pharmacoeconomic
outcome of using first-generation antihistamines seems to
be negative by the loss of productivity due to sedation.44
However, some other events occurred with newer
substances. The most serious toxic event reported was theTable 2 Plasma T1/2 and duration of action of anti-H1-antihista
Class and nonproprietary names;
IZ 1st generation; IIZ 2nd generation
Duration of act
values in hours
Ethanolamines
Diphenhydramine$HCl (I) 12
Alkylamines
Dexchlorpheniramine maleate (I) 4e6
Acrivastine (II) 6e8
Piperazines
Hydroxyzine$HCl (I) 6e24
Cetirizine.HCl (II) 12e24
Levocetirizine (II)
Phenothiazines
Promethazine$HCl (I) 4e6
Phtalazinones
Azelastine$HCl (II) 12e24
Piperidines
Loratadine (II) 24
Desloratadine (II) 24
Ebastine (II) 24
Mizolastine (II) 24
Fexofenadine (II) 12e24association between the consumption of astemizole or
terfenadine and the occurrence of prolongation of the QT
interval, leading to the appearance of polymorphic
ventricular arrhythmias, syncope, and even cardiac
arrest.25 Both astemizole and terfenadine were essen-
tially pro-drugs which required hepatic first-pass metab-
olism by CYP3A4, a member of the hepatic cytochrome
P450 family. In most normal subjects, CYP3A4, activity
was sufficient to ensure that the levels of astemizole and
terfenadine in the plasma were below the detection
limits. As the cardiac adverse effects are related directly
to high plasma levels of the unmetabolised parent drug, it
follows that in patients with pre-existing cardiac
dysfunction, such as congenital QT prolongation, the
presence of impaired liver function, due to conditions
such as cirrhosis or ethanol abuse, or concomitant use of
inhibitors of CYP3A4, such as ketoconazole, itraconazole,
and macrolide antibiotics, was one of the main predis-
posing factors for the occurrence of cardiotoxicity.45
Following the recognition of over 200 cases of potentially
fatal cardiac arrhythmias, both terfenadine and astemi-
zole have been withdrawn from the market in most
countries. Finally, the finding that an interaction with
HERG1Kþ channels is the mechanism by which terfenadine
and astemizole caused potentially fatal cardiac arrhyth-
mias has allowed the development of pre-clinical tests,
both in vitro and in vivo, to predict such activity. Thus, all
H1-antihistamines on the market today are free from
clinically demonstrable cardiotoxicity.
Another adverse effect of H1-antihistamines that has
given cause for concern is their potential to cause a degree
of somnolence in some individuals, despite the relatively
short plasma elimination halflife (see Table 2). Most of the
clinical trials report drowsiness, sedation, or somnolence asmines.
ion (approximate
)
Plasma T1/2 (approximate values
in hours)
8
20e24
1.5 (Active metabolite: 2.5)
20
8e10
10e14
20 (Active metabolite: 45)
12 (active metabolite 20)
27
15e19
13
11e15
622 G. Laekeman et al.a common adverse effect. In a post-marketing surveillance
study of fexofenadine, acrivastine, cetirizine, and lor-
atadine involving 43,363 people, the main outcome
measure was sedation or drowsiness.46 It found a signifi-
cantly higher incidence of sedation for acrivastine (Odds
Ratio 2.79, 95% CI 1.69e4.58; P< 0.0001) and cetirizine
(Odds Ratio 3.53, 95% CI 2.07e5.42; P< 0.0001) compared
with loratadine. However, it found no difference between
fexofenadine and loratadine (Odds Ratio 0.63, 95% CI
0.36e1.11; PZ 0.1). No increase in risk of accident or
injury was found with any of the four antihistamines. There
were also no considerations with regard to intermittent or
continuous use.
The majority of sedation studies with H1-antihista-
mines are performed in either healthy individuals or
individuals with mild disease rather than in conditions,
such as severe allergic rhinitis or chronic urticaria, both of
which cause sleep deprivation.47e49 So is drug-induced
daytime somnolence a problem with such patients. Two
studies, one with fexofenadine and the other with levo-
cetirizine, found that chronic urticaria patients taking
regular H1-antihistamine therapy experienced signifi-
cantly less interference with sleep and improved daily
activities.50,51 Two possible reasons may be suggested to
explain the decreased somnolence. The first possibility is
the relief from physical discomfort ensuing from the
psychological status of the patients and the associated
sleep deprivation. The second possibility is the develop-
ment of tolerance to the central nervous sedative effects
of the H1-antihistamines which has been reported
repeatedly to occur after 4e5 days of administration of
both first and second generation.52e54 Thus, although
direct comparisons between continuous and on-demand
therapy with H1-antihistamines have not been performed,
it is tempting to speculate that continuous therapy may be
preferable to reduce somnolence.
An evaluation was made for azelastine (topical use) long-
term continuous treatment versus on-demand. Continuous
use achieved better therapeutic outcomes, as on-demand
use did not significantly reduce allergic inflammation.55
In conclusion, H1-antihistamines are very safe medicines
when taken long term. Of the major H1-antihistamines,
cetirizine and loratadine have been on the market for 20
years and desloratadine, fexofenadine and levocetirizine
for more than 8 years without safety issues arising. In
adults, formal studies of two to three years duration have
shown cetirizine to be safe when given continuously56,57
while in children of 1e2 years of age, both cetirizine and
levocetirizine have been shown to be safe when given for
periods of 18 months. No serious side effects occurred over
that period. There were no significant differences on
behavioural, cognitive or psychomotor development as
compared to placebo treated children. The tools used
were: the Behavior Screening Questionnaire, the McCarthy
Scales of Children Abilities, the General Cognitive Index and
the Global Medical Questionnaire.58e60Nasal corticosteroids
Intranasal corticosteroids are considered relatively safe.7,38
Local adverse effects are usually mild and include mucosalirritation and epistaxis. Nasal septal perforation is rare. The
most commonly reported adverse effects for individual
intranasal corticosteroids are as follows:
 Beclometasone: epistaxis, upper respiratory tract
infection and headache
 Betamethasone: sore throat, flushing and headache
 Budesonide: unpleasant taste, headache, coughing,
nose dryness and epistaxis
 Flunisolide: nasal burning, drowsiness, and nasal
irritation
 Fluticasone: headache, epistaxis, sore throat, nasal
dryness/blowing and diarrhoea. There have been case
reports of anaphylaxis and flushing as well as central
nervous system, cardiac, and dermatological reactions
 Mometasone: headache, epistaxis, and pharyngitis. In
clinical trials, the rate of treatment discontinuation
with mometasone furoate nasal spray because of
adverse events was 3%, a rate similar to those
reported with placebo and active controls; the most
frequently reported adverse effects were headache,
viral infection, pharyngitis, and epistaxis
 Triamcinolone: headache, sneezing, and nasal
irritation
As for the antihistamines, no comparative data are
available for continuous versus on-demand therapy. Clinical
and histopathological examination of nasal mucosa after
long-term intranasal budesonide or mometasone use has
failed to show significant changes.38 Although intranasal
steroids can result in systemic bioavailability, no significant
adverse effects have been reported on bone metabolism.
Influence of adrenal function should be considered. Based
on morning salivary cortisol concentrations, for 58% of
patients on nasal betamethasone sodium phosphate and for
4% of patients on mometasone furoate biochemical
evidence of adrenal suppression was apparent.61 Mometa-
sone 100 mg/day does neither influence growth in children
between 3 and 9 years old, nor interfere with the hypo-
thalamicepituitaryeadrenocortical-axis function. The
compliance was high, but no details are given about the
therapeutic efficacy.62
What are the cost and cost-effectiveness
implications of continuous versus ‘on-demand’
therapy?
To date, no study has compared costs of continuous and on-
demand treatment of allergic rhinitis. As it is difficult to
determine the economic impact of allergic rhinitis, Table 3
identifies the major cost items that need to be considered
when contrasting costs of continuous and on-demand
treatment of allergic rhinitis from a societal perspective. In
addition to direct healthcare costs, studies need to focus on
eliciting direct non-healthcare costs and indirect costs.
With respect to the latter, attention needs to be paid to
calculate the indirect costs of days lost to education and
work, costs of reduced productivity at work, and the costs
of reduced ability to carry out usual daily activities. Indi-
rect costs need to be calculated for patients suffering from
allergic rhinitis.
Table 3 Cost items of continuous/on-demand treatment of allergic rhinitis.
Direct healthcare costs Direct non-health
care costs
Indirect costs
Medication Healthcare providers Other
Oral and intranasal
antihistaminics
General practitioner Diagnostic tests Transportation to
healthcare provider
Absence from work
Intranasal
corticosteroids
Pneumologist Immunotherapy Child care costs
while in treatment
Reduced productivity at work
Oral and intranasal
decongestants
Ear, nose and
throat specialist
Accident and
Emergency visit
Home adaptations Time lost from education
Intranasal
anticholinergic
agents
Alternative medicine
(e.g. homeopathy)
Reduced ability to carry out
usual daily activities
Therapy of allergic rhinitis: continuous or on-demand? 623One cost-effectiveness analysis investigated contin-
uous versus on-demand treatment in a small sample of
children during six months.22 Continuous treatment con-
sisted of the daily administration of cetirizine 5 mg.
Alternatively, children received placebo. However, both
groups of children were allowed to use rescue or symp-
tomatic drugs when needed. Suggested rescue medication
was cetirizine, inhaled salbutamol, inhaled fluticasone
and short courses of systemic corticosteroids. The
assessment of costs was limited to drug costs. The authors
found that continuous treatment dominated on-demand
treatment: continuous treatment with cetirizine resulted
in better symptom control of allergic rhinitis and of
asthma, and in lower drug costs as compared to on-
demand treatment. There is a need for prospective
economic evaluations alongside clinical trials comparing
continuous and on-demand treatment of allergic rhinitis,
with a sufficient number of patients and length of treat-
ment period.
Conclusions
This review has examined the pharmacotherapeutic
evidence for the use of continuous treatment in comparison
with an on-demand regimen (Fig. 1). Clearly, for cortico-
steroids, their mechanism of action in allergic rhinitis of
reducing allergic inflammation requires continuous therapy
at least for the duration of symptoms. For H1-antihista-
mines the conclusion is equivocal. Some trials suggest that
continuous treatment is preferable but more studies are
needed to confirm this. For both H1-antihistamines and
nasal corticosteroids safety data indicate that continuous
treatment may be given without fears of adverse conse-
quences. With regard to the cost and cost-effectiveness
implications of continuous therapy versus on-demand
therapy, more studies are necessary before definitive
conclusions may be made.
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